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Recent studies demonstrated that PARP-1 [poly(ADP-ribose) polymerase-1] inhibitors kill breast cancer 
associated gene-1 and –2 (BRCA1/2) deficient cells with extremely high efficiency while BRCA+/- and 
BRCA+/+ cells are relatively non-responsive to the treatment. It was therefore proposed that PARP-1 inhibitors 
might be the long-sought genetically specific drugs that are both safe and effective for treating BRCA1/2-
associated breast cancers. However, a report published in a recent issue of the International Journal of Biological 
Sciences revealed that PARP-1 inhibitors, although able to kill naïve BRCA1 mutant cells with high specificity 
both in vitro and in vivo, exhibit minimal specificity in inhibiting the growth of mouse mammary tumor cells 
irrespective of their BRCA1 status in allograft nude mice. Non-specific inhibition in human BRCA1+/+, 
BRCA1+/-, and BRCA1-/- breast cancer cells by PARP-1 inhibitors was also observed. Additional mutations 
occurring during cancer progression may be a culprit, although the exact cause for the resistance of BRCA1-/- 
breast cancer cells to PARP-1 inhibitors remains elusive. These findings suggest that PARP inhibition may serve 
as an approach for the prevention of BRCA related breast cancer and may be useful in combination with other 
chemotherapeutic agents in the treatment of breast cancer. 
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1.  Introduction 
Breast cancer is the leading cause of cancer 
incidence and the second leading cause of cancer 
mortality in women.  Familial breast cancer is a small 
subset of this disease contributing to about 5 to 10% of 
breast cancer cases.  Germline mutations of the breast 
tumor suppressor genes BRCA1 and BRCA2 have been 
found to contribute to most of the familial breast 
cancer cases [1-5]. BRCA1 was mapped in 1990 [6] and 
cloned in 1994 [7]. Numerous studies in the past 
decade have revealed that BRCA1-deficiency results 
in genetic instability, primarily due to centrosome 
amplification, defective cell cycle checkpoint, and 
impaired DNA damage repair (reviewed in [8-15]). 
Hence, BRCA1 is essential for maintaining genome 
integrity while genetic instability associated with 
BRCA1 deficiency is responsible for breast cancer 
formation [16, 17]. 
One of the major causes of the genetic instability 
associated with BRCA1 deficiency is that BRCA1 
mutant cells have an impaired ability to undergo 
homologous recombination (HR) [12, 14, 18-20], and 
therefore cannot effectively repair HR-mediated DNA 
damage, such as DNA double strand breaks (DSBs). In 
the absence of BRCA1, DSBs can be gradually 
accumulated, which may result in the activation of 
oncogenes and inactivation of tumor suppressor genes, 
eventually leading to tumor formation. On the other 
hand, defective DNA damage repair may also make 
BRCA1 deficient cancer cells more sensitive to DNA 
damaging agents, such as irradiation, Mitomycin C 
(MMC), and adriamycin [19, 21-23].  Thus, one of the 
therapeutic approaches to kill BRCA1 deficient cancer 
cells efficiently is treating these cells with DNA 
damaging reagents thereby introducing acute DNA 
damage. However, the majority DNA damage 
reagents are not specific and can cause the similar 
extent of damage in both BRCA1 mutant and wild 
type cells. More recently it was shown that PARP-1 
inhibitors could kill BRCA1/2 deficient cells with high 
specificity bringing great promise to the BRCA1 
cancer patient [24, 25]. Here we will review the current 
progress of PARP-1 inhibitors in the chemoprevention 
and therapeutic treatment of BRCA1/2-associated 
breast cancers and discuss possible options for using 
these drugs efficiently. 
2.  PARP-1 inhibitors as potential 
chemotherapeutic drugs 
Using a clonogenic survival assay, Bryant et al. 
(2005) found that a BRCA2-deficient cell line V-C8, 
compared with the BRCA2 wild type control, 
exhibited extreme sensitivity to AG14361, a very 
potent PARP-1 inhibitor (KI=5nM), and NU1025, a 
moderately potent PARP-1 inhibitor (KI  =50nM). 
NU1025 treatment also profoundly reduced colony 
formation (up to 100 fold) of MCF-7 and MDA-MB-
231 cells when BRCA2 was depleted by RNAi 
compared with untreated control cells [24]. Studying Int. J. Med. Sci. 2006, 3    118
mouse embryonic stem (ES) cells carrying targeted 
mutations of BRCA1 (homozygous deletion of exons 
22-24, referred to as BRCA1-/-) or BRCA2 
(trEx11/ΔEx27, referred to as BRCA2-/-), Farmer et al. 
(2005) revealed similar sensitivity of these cells to 
PARP-1 inhibitors in vitro [25].  
Will this work in vivo? To investigate this, both 
groups transplanted BRCA2-deficient ES cells [25] or 
V-C8 cells [24] into athymic nude mice and treated the 
xenografted tumors with PARP-1 inhibitors. Their 
data revealed that PARP-1 inhibition completely 
blocked the growth of BRCA2-deficient tumors, but it 
h a d  n o  e f f e c t  o n  B R C A 2 - w i l d  t y p e  t u m o r s .  I t  w a s  
subsequently suggested that PARP-1 inhibition might 
represent a new concept in cancer treatment for 
BRCA1/2 mutation carriers.  
Why are BRCA1- and BRCA2-deficient cells 
extremely sensitive to PARP-1 inhibition? The 
products of the genes, BRCA1, BRCA2 and PARP-1, 
are nuclear proteins and are critical components of the 
cellular response to DNA damage [12, 14, 18-20, 26-28]. 
PARP-1 binds to and efficiently repairs DNA single 
strand breaks (SSBs) formed during base excision 
repair (BER) of small DNA adducts induced by 
alkylating agents or ionizing radiation [29]. It has been 
shown that PARP-1 inhibition leads to persistent 
single strand breaks (SSBs) in DNA [27], which result 
in formation of double strand breaks (DSBs) when 
they meet at replication forks (Fig. 1A). In the presence 
of wild type BRCA1 and BRCA2, DSBs can be 
efficiently repaired by RAD51 mediated homologous 
recombination (Fig. 1B). It has been shown that 
BRCA1 and BRCA2 interact with RAD51, and play 
essential role in homologous recombination [28, 30, 
31]. Thus, in the event of DNA damage associated 
with PARP inhibition, BRCA1 or BRCA2 mutant cells 
cannot repair DNA DSBs properly, leading to the 
collapse of replication forks, and illegitimated DNA 
ends joining, consequently leading to growth arrest 
and apoptosis (Fig. 1C). This model provides a 
molecular basis for the reason that why BRCA1- and 
BRCA2-deficient cells are extremely sensitive to 
PARP-1 inhibition.  
Figure 1. A model showing DSB formation and DNA rearrangement in the absence of BRCA and PARP1. (A) PARP-1 
binds and repairs single strand breaks (SSBs) in DNA. These SSBs result in formation of double strand breaks (DSBs) when 
they meet replication forks. (B) In the presence of wild type BRCA1 and BRCA2, DSBs can be efficiently repaired by 
RAD51 mediated homologous recombination (HR). (C) BRCA1 or BRCA2 mutant cells cannot repair DNA DSBs properly 
upon the inhibition of PARP, leading to DNA replication arrest and illegitimated DNA ends joining. 
 
3.  Can PARP-1 inhibitors specifically kill human BRCA2-deficient pancreatic cancer cells? 
Because PARP-1-null mice are viable and healthy [32], and inhibitors that are specific for PARP-1 are 
relatively non-toxic and do not directly damage DNA, PARP-1 inhibitors might be both safe and effective for 
BRCA1/2-associated breast cancers. However, it is noticed that these data were obtained by using non-
cancerous and genetically naïve BRCA1/2-/- ES cells, BRCA2-/- V-C8 hamster cells, and two BRCA2-proficient 
breast cancer cell lines, MCF-7 and MDA-MB-231, that carried acute suppression of BRCA2 by siRNA. Cancer 
cells originated from naturally occurring BRCA1/2 mutations were not tested. To investigate this, Gallmeier and 
Kern (2005) treated a cell line CAPAN1, which harbors the frequent, naturally occurring BRCA2 6174delT 
frameshift mutation accompanied by loss of the second allele with NU1025 and 3-aminobenzamide (3AB), a 
weak PARP-1 inhibitor with the KI=500nM [33]. Their data indicated that PARP inhibition by these drugs did 
not result in significant cell death of CAPAN1 cells. This observation casts doubt about the uniformity of the 
specific cell killing of BRCA2-deficient cells upon PARP inhibition. This observation also urged caution as to 
whether prior findings were fully generalizable for the specific treatment of human cancers harboring naturally 
occurring, inactivating forms of BRCA2 mutations.  Int. J. Med. Sci. 2006, 3    119
The finding that CAPAN1 cells are relatively insensitive to NU1025 was quickly confirmed [34]. McCabe et 
al. (2005) compared sensitivity of the CAPAN1 cells to 4 PARP inhibitors, including NU1025, KU0051529 (a 
weak PARP inhibitor, IC50 730 nM) and two very potent PARP inhibitors, KU0058684 (IC50 3.2 nM) and 
KU0058948 (IC50 3.4 nM). Their data showed that the CAPAN1 cells were indeed extremely sensitive to the two 
potent PARP inhibitors although they were much less sensitivity to NU1025 and KU0058948. These results 
indicate that treatment with potent PARP inhibitors might still be an exciting potential therapy for cancers 
involving BRCA2 deficiency [34].  
However, the puzzle has not been fully solved. NU1025 was previously reported to kill BRCA2-depleted 
MCF-7 and MDA-MB-231 cells with extremely high efficiency, i.e. 100-fold reduction in colony formation at 
about 10 μM of NU1025 [24]. In contrast, in CAPAN1 cells, this dose of NU1025 [34] and even at much higher 
concentrations up to 200 μM [33] failed to exhibit any specific killing. While the reason for this discrepancy 
remains unclear, it was proposed that genetic alterations during tumor progression due to genetic instability 
associated with BRCA1- and BRCA2-deficiency might be a culprit [33]. In other words, some specific mutations 
might block the sensitivity of BRCA1/2-/- cancer cells to PARP-1 inhibition.  
Consistent with this, it was shown recently that the chicken DT40 PARP-1-/- mutant cells displayed 
reduced levels of homologous recombination (HR) and were sensitive to various double strand break (DSB)-
inducing genotoxic agents [35]. Interestingly, when either Ku-70 or Ligase IV was also mutated, the PARP-1-/- 
cells became resistant to the killing by DSB-inducing drugs. The underlying mechanism is that the absence of 
Ku70 or ligase IV prevents illegitimated DNA ends ligation of DNA fragments by non-homologous mediated 
end joining (NHEJ) in PARP-1-/- cells, therefore, preventing their lethality (Fig. 2). This study provides an 
example that lethality associated with DSBs and PARP-1 inhibition could indeed be rescued by specific types of 
mutations. 
Figure 2. A model showing how Ku70 or ligase IV deficiency represses lethality caused by DSB inducing agents in PARP-
1-/- DT40 cells. (A) Treatment of DSB inducing agents in PARP-1-/- DT40 cells decreases ability of HR (HR*) and causes 
DSBs. (B) Ku-70 protein competes with HR machinery and binds to DSBs, directing the repair toward the non-homologous 
end joining (NHEJ), where ligase IV (LIG4) also plays an important role. This results in lethality of PARP-1-/- cells. (C) 
The absence of Ku70 or Ligase IV prevents illegitimated DNA end ligation of DSBs through NHEJ in PARP-1-/- cells. This 
allows more time for PARP-1 deficient cells to repair DSBs, therefore, preventing their lethality.  
 
4.  Can PARP-1 inhibitors specifically kill BRCA1 mutant breast cancer cells? 
These observations cast significant doubts on the effectiveness and specificity of PARP inhibition on BRCA 
associated tumorigenesis. Furthermore, previous in vivo studies only tested two cell lines, BRCA2 mutant ES 
cells and C-V8 cells while BRCA1 mutant breast cancer cells were not used. To provide a study with more 
clinical relevance, we compared sensitivity to PARP inhibition of 12 cell lines, including ES cells, mouse 
mammary tumor cells, and human breast cancer cells using three PARP inhibitors: AG14361, NU1025, and 3-
aminobenzamide (3AB) [36].   
We first tested a BRCA1 mutant ES cell line [BRCA1trEx11/Δ11 that carries one BRCA1 mutant allele truncated 
at exon 11 [37] and one allele with a deletion of exon 11 by a Cre-LoxP approach [38], referred to as BRCA1-/-]. 
Our data revealed that the BRCA1-/- cells were significantly more sensitive to AG14361 treatment than 
BRCA1+/- and BRCA1+/+ ES cells both in vitro and in vivo. Indeed, AG14361 treatment completely blocked 
tumor growth in 90% nude mice that had received transplantation of BRCA1-/- ES cells. Only one tumor that 
escaped PARP inhibition grew, though much slower compared with tumors developed in the nude mice that 
had received transplanted BRCA1+/+ ES cells. Next, we tested sensitivity to PARP inhibition using three 
mammary tumor cell lines that are either hypomorphic (BRCA1
Δ11/Δ11) or null (BRCA1-/-) for BRCA1. In the 
colonogenic assay, we found that all BRCA1-/- cell lines were much more sensitive to the potent PARP inhibitor Int. J. Med. Sci. 2006, 3    120
AG14361 than BRCA1+/+ tumor cells (Fig. 3A). However, AG14361 treatment exhibited only mild specificity in 
mouse BRCA1-/- mammary cancer cells (Fig. 3B) in comparison with their controls (Fig. 3C) in the xenografted 
nude mice. These observations indicated that BRCA1-/- mammary cancer cells are indeed much more resistant 
to PARP inhibition than BRCA1-/- ES cells in the allograft model. Finally, we studied response to PARP- 
inhibition of four human breast cancer cell lines: MCF-7 (BRCA1+/+), MDA-MB-231 (BRCA1+/-), HCC1937 
(BRCA1-/-) and SUM1315MO2 (BRCA1-/-). Using both clonogenic survival assay and MTT assay, we found 
that PARP-1 inhibitors seem to have a similar inhibition effects on their growth regardless of the BRCA1 
genotypes (Fig. 3D) [36]. 
We believe that the non-cancerous cells are generally naïve, whereas tumor cells represent cells that have 
had multiple genetic mutations and that in a tumor there may be numerous fundamentally different cancer cells 
when classified by the type and frequency of individual genomic changes. It has been shown that tumorigenesis 
involves alterations of at least 6 major biological pathways/processes [39]. Indeed, our work in BRCA1 mutant 
mouse models have also revealed numerous genetic/molecular alterations in BRCA1 mutant tumors, and have 
demonstrated that BRCA1-associated tumorigenesis has been selected to survive genomic changes [21, 22, 38, 
40-43]. This may account for the differential resistance to PARP inhibition observed between BRCA mutant 
cancer cells and pre-cancerous cells [36].  
Figure 3. Effect of a potent PARP-1 inhibitor, AG14361, on BRCA1 mutant and control cancer cells. (A) Clonogenic 
survival assay. Five hundred 780 (BRCA1Δ11/Δ11), and 525 (BRCA1-/-), and NEU (BRCA1+/+) cells were exposed to 
AG14361 for 10 consecutive days, 18 hours after plating. (B,C) Response of in vivo allograft of BRCA1-/- (B), and 
BRCA1+/+ (C) mammary tumor cells to AG14361. The recipient nude mice were treated intra-peritoneally with AG14361 
(30 mg/kg) 24 hours after transplantation of 1 X 10
6 cells for three consecutive days starting on days 2, 9 and 16 (arrows). 
Our data indicated that the treatment failed to achieve a more than marginal specific killing of BRCA1 mutant cancer cells 
as both BRCA1-/- and BRCA1+/+ cells showed about a 30-40% reduction in growth. (D) Clonogenic assay. MCF-7, MDA-
MB-231 and HCC1937 cells were treated and exposed to AG14361 continuously for 10 days. 
 
5.  PARP inhibition remains promising in chemoprevention and therapeutic treatment for BRCA related 
breast cancer 
Clearly, a common finding among above studies is that BRCA-/- pre-cancerous cells are very sensitive to 
PARP inhibition than wild type cells while cancer cells  exhibit different response to PARP inhibition under 
different conditions [24, 25, 33, 34, 36]. Animal studies showed that BRCA1- and BRCA2-deficient embryos die 
during embryonic development [37, 44-46]. Adults with BRCA1/2 associated hereditary breast cancer inherit 
one mutated allele through their germline and later suffer loss of heterozygosity of the wild type allele in order Int. J. Med. Sci. 2006, 3    121
for breast cancer to arise. There must be at least one previous mutation in another gene however, that is 
permissive, for viability of the cell in the event of a second BRCA mutation. Current data suggest that ATM, 
CHK2 and p53 may be candidate genes for these permissive mutations as impaired functions of these genes, 
either at heterozygous or homozygous forms, attenuates apoptosis induced by BRCA1 deficiency and allows 
mutant embryos survive to adulthood  [40, 42]. The extended survival of BRCA deficient cells allows for further 
genomic alterations leading to the eventual development of cancer.  
Thus, we propose that the BRCA associated tumorigenesis may be divided into two phases regarding 
sensitivity to PARP inhibition (Fig. 4). In the early stages of tumorigenesis, BRCA1 mutant cells are sensitive to 
PARP inhibition. Evidence indicates that treatment of BRCA2-deficient small intestine with a potent PARP-1 
inhibitor results in high levels of apoptosis 6-12 hours after treatment [47]. It was shown that p53 deficiency in 
MDA-MB-231 cells did not render resistance of these cells to PARP inhibition upon siRNA mediated deletion of 
PARP1 [24]. This suggests that BRCA deficient cells that have recently received a permissive mutation, such as 
p53, might still be sensitive to PARP-1 inhibitors in this pre-cancerous state.  
However, in the second stage of tumorigenesis, BRCA deficient tumor cells may become insensitive to 
PARP inhibition due to additional mutations (Fig. 4). In this regard, we showed that HCC1937 (5832insC) and 
SUM1315M02 (185delAG), which both produce a truncated and inactive form of BRCA-1 which together 
account for up to 85% of BRCA-1 pathogenic mutations in humans, were not any more sensitive to PARP-1 
inhibitors than wild type or heterozygous mammary tumor cell lines.  
Despite a difficulty to identify mutations that render the resistance of BRCA cancer cells to PARP inhibition, 
there is evidence to suggest that PARP inhibitors may be useful in treating tumors in combination with cytotoxic 
drugs by increasing the sensitivity of the tumors to these agents. Indeed, it has been shown that PARP-1 
inhibitors not only significantly enhance the anti-tumor efficacy of the alkylating agent temozolomide (TMZ) in 
solid or hematological tumors, but also, restore the sensitivity to TMZ in resistant tumors [48, 49]. In addition, 
PARP-1 inhibitors have also been shown to similarly sensitize tumors cells to the topoisomerase I inhibitor, 
irinotecan in colon carcinomas [50, 51]. Furthermore, unpublished data from this lab suggest that PARP-1 
inhibitors may also show synergism with some anti-metabolites and anti-mitotic agents. PARP-1 inhibitors also 
are attractive agents based on what seems to be not only few side effects but also a protective effect in normal 
tissue. Indeed, reports from clinical trials using PARP-1 inhibitors have successfully completed phase I studies 
and entered phase II studies for various ischemic disorders [52]. Furthermore, PARP-1 inhibitors seem to protect 
against the cardiotoxicity of doxorubicin and the nephrotoxicity of cisplatin [53, 54]. The use of PARP-1 
inhibitors in combination with standard chemotherapeutic agents also, seems attractive in the sense that by 
sensitizing tumor cells to cytotoxic agents one might be able to give a lower dose and maintain the same relative 
efficacy while at the same time reducing the toxic side effects.  
Figure 4. A model depicting BRCA1 associated tumorigenesis in regarding to the development of PARP resistance. In 
familial cancer, one mutant BRCA1 allele is inherited from the germline.  One additional mutation in the BRCA1 locus 
(LOH) results in a BRCA1 deficiency, which could result in genetic instability, activation of p53-dependent cell cycle 
checkpoints and apoptosis pathways, leading to growth arrest and cell death.  However, genetic instability triggered by 
BRCA1 loss could facilitate mutations in general. When permissive mutations, such as ATM, CHK2 or p53 heterozygous or 
homozygous mutations, occur, BRCA1-/- cells survive. Cells in this phase may be sensitive to PARP inhibition. However, 
PARP resistance may develop when further genetic alterations occur leading to full growth of breast cancers. 
 
6.  Summary  
We have reviewed the current data suggesting 
that PARP inhibition may serve as potent approach 
for prevention of BRCA related breast cancer. 
However, the use of this strategy for therapeutic 
treatment for hereditary breast cancers is dependent 
on the continued susceptibility of BRCA mutant cells Int. J. Med. Sci. 2006, 3    122
to PARP inhibitors, which may be achieved by using a 
combination with other reagents. The future use of 
PARP-1 inhibitors as safe and efficacious agents in 
preventing the hereditary form of breast cancer and as 
sensitizing agents in the treatment of breast cancer 
seems bright. Clinical trials are needed to elucidate the 
best use of PARP inhibitors in combination of other 
therapeutic drugs in reducing the morbidity and 
mortality of breast cancers. 
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